Share Price and Basic Stock Data
Last Updated: January 23, 2026, 4:39 pm
| PEG Ratio | 108.53 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
ERIS Lifesciences Ltd operates in the pharmaceuticals sector and reported a market capitalization of ₹19,145 Cr, with its stock priced at ₹1,380. The company has shown a consistent revenue growth trajectory, with sales increasing from ₹1,347 Cr in FY 2022 to ₹1,685 Cr in FY 2023, and further projected to reach ₹2,894 Cr in FY 2025. Quarterly sales also reflect this upward trend, rising from ₹461 Cr in September 2022 to ₹505 Cr in September 2023, with an expected increase to ₹792 Cr by September 2025. The operating profit margin (OPM) has remained relatively stable, with a reported OPM of 36% in recent quarters. However, the company’s growth is coupled with rising expenses, which increased from ₹1,146 Cr in FY 2023 to ₹1,876 Cr in FY 2025. This highlights the company’s ongoing investment in growth, although it may pressure margins if not managed effectively. Overall, ERIS Lifesciences demonstrates strong revenue growth, positioning itself favorably within the competitive pharmaceuticals landscape.
Profitability and Efficiency Metrics
ERIS Lifesciences reported a net profit of ₹449 Cr for the trailing twelve months (TTM), translating to a net profit margin of 12.94% for FY 2025. The company’s return on equity (ROE) stood at 12.9%, while the return on capital employed (ROCE) was reported at 12.2%. The operating profit has shown fluctuations, with a high of ₹539 Cr in FY 2023 and a projected increase to ₹1,018 Cr in FY 2025, reflecting a robust operating profit margin of 35% for the same fiscal year. The interest coverage ratio (ICR) of 4.48x indicates that the company comfortably meets its interest obligations, although it has seen a decline from previous years, suggesting an increase in financial leverage. Additionally, the cash conversion cycle (CCC) of 59 days indicates effective management of working capital, although the rising days payable may impact liquidity. Overall, ERIS Lifesciences exhibits solid profitability metrics, but the increasing borrowings and related interest expenses warrant close monitoring.
Balance Sheet Strength and Financial Ratios
As of September 2025, ERIS Lifesciences reported total assets of ₹7,160 Cr, with total liabilities standing at ₹6,744 Cr, resulting in a debt-to-equity ratio of 0.84x. This indicates a balanced capital structure, although the long-term debt-to-equity ratio of 0.60x suggests a reliance on debt financing that has increased over the years. Reserves have grown to ₹3,078 Cr, reflecting the company’s ability to retain earnings for reinvestment. The company’s book value per share increased to ₹209.57 in FY 2025, which is a positive indicator of shareholder equity. However, the current ratio of 0.88x indicates potential liquidity concerns, as it falls below the typical sector benchmark of 1.0, suggesting that the company may face challenges in meeting short-term obligations. The overall financial health remains strong, but the increasing borrowings and declining liquidity ratios highlight areas for cautious management.
Shareholding Pattern and Investor Confidence
ERIS Lifesciences has a diverse shareholding structure, with promoters holding 54.85% of the company as of September 2025. Foreign institutional investors (FIIs) have reduced their stake to 7.21%, down from 15.50% in December 2022, indicating a potential decline in foreign investor confidence. Domestic institutional investors (DIIs) have increased their holdings to 19.36%, suggesting a positive outlook from local investors. The public holding stands at 18.57%, with a total of 59,438 shareholders, which reflects a stable retail investor base. The reduction in FIIs could be a concern, as it may indicate a shift in sentiment, possibly due to the rising leverage and expenses. However, the increasing confidence from DIIs may counterbalance this trend. Overall, while the promoter stake remains strong, the shifting dynamics in institutional ownership may influence future market perceptions and investor confidence.
Outlook, Risks, and Final Insight
ERIS Lifesciences is positioned to benefit from growing revenue trends, with a focus on expanding its market presence in the pharmaceutical sector. However, the company faces risks associated with rising expenses and increased debt levels, which could pressure profitability if not managed effectively. Additionally, the declining liquidity ratios may pose challenges in meeting short-term financial obligations. On the positive side, the strong operating profit margins and growing reserves provide a buffer against potential downturns. The company’s ability to maintain its profitability while managing its debt will be critical for sustaining investor confidence. Future growth may depend on strategic investments and operational efficiencies, particularly as the competitive landscape evolves. Monitoring these dynamics will be essential for stakeholders as ERIS Lifesciences navigates its growth journey amidst the challenges and opportunities in the pharmaceutical sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 123 Cr. | 98.0 | 203/84.3 | 27.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,696 Cr. | 340 | 479/192 | 76.5 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.0 Cr. | 41.6 | 42.0/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,646.15 Cr | 1,095.96 | 48.16 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 461 | 423 | 403 | 467 | 505 | 486 | 551 | 720 | 741 | 727 | 705 | 773 | 792 |
| Expenses | 309 | 286 | 284 | 297 | 324 | 311 | 402 | 470 | 477 | 477 | 453 | 496 | 504 |
| Operating Profit | 151 | 137 | 119 | 170 | 181 | 176 | 148 | 250 | 265 | 250 | 252 | 277 | 288 |
| OPM % | 33% | 32% | 30% | 36% | 36% | 36% | 27% | 35% | 36% | 34% | 36% | 36% | 36% |
| Other Income | 5 | 2 | 1 | 1 | 3 | 4 | 15 | 2 | 5 | 4 | 8 | 4 | 3 |
| Interest | 7 | 3 | 9 | 17 | 16 | 18 | 33 | 60 | 59 | 57 | 54 | 49 | 50 |
| Depreciation | 29 | 30 | 35 | 41 | 42 | 46 | 54 | 76 | 80 | 81 | 77 | 71 | 69 |
| Profit before tax | 121 | 107 | 76 | 112 | 126 | 116 | 77 | 116 | 129 | 116 | 129 | 161 | 173 |
| Tax % | 1% | 6% | 19% | 17% | 3% | 12% | -4% | 22% | 25% | 25% | 21% | 22% | 22% |
| Net Profit | 119 | 100 | 61 | 94 | 122 | 101 | 80 | 90 | 96 | 87 | 102 | 125 | 134 |
| EPS in Rs | 8.85 | 7.49 | 4.81 | 6.98 | 9.07 | 7.55 | 5.22 | 6.12 | 6.73 | 6.15 | 6.89 | 8.66 | 8.82 |
Last Updated: January 1, 2026, 8:36 pm
Below is a detailed analysis of the quarterly data for ERIS Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 792.00 Cr.. The value appears strong and on an upward trend. It has increased from 773.00 Cr. (Jun 2025) to 792.00 Cr., marking an increase of 19.00 Cr..
- For Expenses, as of Sep 2025, the value is 504.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 496.00 Cr. (Jun 2025) to 504.00 Cr., marking an increase of 8.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 288.00 Cr.. The value appears strong and on an upward trend. It has increased from 277.00 Cr. (Jun 2025) to 288.00 Cr., marking an increase of 11.00 Cr..
- For OPM %, as of Sep 2025, the value is 36.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 36.00%.
- For Other Income, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Jun 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 50.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 49.00 Cr. (Jun 2025) to 50.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 69.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 71.00 Cr. (Jun 2025) to 69.00 Cr., marking a decrease of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 173.00 Cr.. The value appears strong and on an upward trend. It has increased from 161.00 Cr. (Jun 2025) to 173.00 Cr., marking an increase of 12.00 Cr..
- For Tax %, as of Sep 2025, the value is 22.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 22.00%.
- For Net Profit, as of Sep 2025, the value is 134.00 Cr.. The value appears strong and on an upward trend. It has increased from 125.00 Cr. (Jun 2025) to 134.00 Cr., marking an increase of 9.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 8.82. The value appears strong and on an upward trend. It has increased from 8.66 (Jun 2025) to 8.82, marking an increase of 0.16.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:24 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 509 | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,894 | 2,998 |
| Expenses | 414 | 427 | 425 | 480 | 533 | 637 | 702 | 781 | 858 | 1,146 | 1,332 | 1,876 | 1,931 |
| Operating Profit | 95 | 118 | 172 | 269 | 322 | 345 | 372 | 431 | 489 | 539 | 677 | 1,018 | 1,068 |
| OPM % | 19% | 22% | 29% | 36% | 38% | 35% | 35% | 36% | 36% | 32% | 34% | 35% | 36% |
| Other Income | 9 | 7 | 3 | 25 | 26 | 31 | 12 | 9 | 22 | 9 | 22 | 18 | 19 |
| Interest | 0 | 0 | 0 | 1 | 11 | 23 | 2 | 2 | 4 | 26 | 85 | 231 | 210 |
| Depreciation | 5 | 16 | 20 | 23 | 26 | 36 | 50 | 43 | 65 | 117 | 183 | 315 | 298 |
| Profit before tax | 98 | 109 | 154 | 270 | 312 | 317 | 331 | 394 | 442 | 405 | 431 | 489 | 579 |
| Tax % | 28% | 18% | 13% | 9% | 6% | 8% | 11% | 10% | 8% | 8% | 8% | 23% | |
| Net Profit | 71 | 89 | 135 | 247 | 295 | 291 | 297 | 355 | 406 | 374 | 397 | 375 | 449 |
| EPS in Rs | 5,121.45 | 6,489.45 | 9,714.18 | 17.95 | 21.39 | 21.15 | 21.84 | 26.16 | 29.88 | 28.10 | 28.82 | 25.84 | 30.52 |
| Dividend Payout % | -0% | -0% | 63% | -0% | -0% | -0% | 13% | 21% | 20% | 26% | -0% | 28% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.35% | 51.69% | 82.96% | 19.43% | -1.36% | 2.06% | 19.53% | 14.37% | -7.88% | 6.15% | -5.54% |
| Change in YoY Net Profit Growth (%) | 0.00% | 26.33% | 31.28% | -63.53% | -20.79% | 3.42% | 17.47% | -5.16% | -22.25% | 14.03% | -11.69% |
ERIS Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 22% |
| 3 Years: | 29% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 4% |
| 3 Years: | -5% |
| TTM: | 2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 37% |
| 1 Year: | 21% |
| Return on Equity | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 18% |
| 3 Years: | 16% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 3:40 am
Balance Sheet
Last Updated: January 7, 2026, 3:38 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.14 | 0.14 | 0.14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 176 | 266 | 299 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,895 | 2,182 | 2,573 | 2,841 | 3,078 |
| Borrowings | 1 | 1 | 0 | 1 | 377 | 176 | -0 | 7 | 84 | 877 | 2,781 | 2,478 | 2,389 |
| Other Liabilities | 94 | 91 | 98 | 124 | 170 | 175 | 205 | 202 | 233 | 337 | 1,366 | 1,412 | 1,680 |
| Total Liabilities | 271 | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,744 | 7,160 |
| Fixed Assets | 75 | 72 | 71 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,319 | 5,306 | 5,217 |
| CWIP | -0 | -0 | -0 | 0 | -0 | 3 | 4 | 2 | 27 | 22 | 20 | 67 | 122 |
| Investments | 84 | 167 | 190 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 | 68 |
| Other Assets | 112 | 119 | 136 | 157 | 271 | 383 | 544 | 636 | 761 | 783 | 2,379 | 1,304 | 1,753 |
| Total Assets | 271 | 357 | 397 | 692 | 1,408 | 1,502 | 1,502 | 1,785 | 2,226 | 3,410 | 6,734 | 6,744 | 7,160 |
Below is a detailed analysis of the balance sheet data for ERIS Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,078.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,841.00 Cr. (Mar 2025) to 3,078.00 Cr., marking an increase of 237.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,389.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,478.00 Cr. (Mar 2025) to 2,389.00 Cr., marking a decrease of 89.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,680.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,412.00 Cr. (Mar 2025) to 1,680.00 Cr., marking an increase of 268.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 7,160.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,744.00 Cr. (Mar 2025) to 7,160.00 Cr., marking an increase of 416.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 5,217.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,306.00 Cr. (Mar 2025) to 5,217.00 Cr., marking a decrease of 89.00 Cr..
- For CWIP, as of Sep 2025, the value is 122.00 Cr.. The value appears strong and on an upward trend. It has increased from 67.00 Cr. (Mar 2025) to 122.00 Cr., marking an increase of 55.00 Cr..
- For Investments, as of Sep 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 67.00 Cr. (Mar 2025) to 68.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,753.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,304.00 Cr. (Mar 2025) to 1,753.00 Cr., marking an increase of 449.00 Cr..
- For Total Assets, as of Sep 2025, the value is 7,160.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,744.00 Cr. (Mar 2025) to 7,160.00 Cr., marking an increase of 416.00 Cr..
Notably, the Reserves (3,078.00 Cr.) exceed the Borrowings (2,389.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 94.00 | 117.00 | 172.00 | 268.00 | -55.00 | 169.00 | 372.00 | 424.00 | 405.00 | -338.00 | 675.00 | -1.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 16 | 16 | 16 | 24 | 28 | 31 | 53 | 42 | 44 | 63 | 77 | 58 |
| Inventory Days | 166 | 223 | 178 | 195 | 178 | 196 | 148 | 145 | 166 | 136 | 182 | 171 |
| Days Payable | 138 | 142 | 92 | 134 | 247 | 200 | 213 | 157 | 166 | 129 | 210 | 170 |
| Cash Conversion Cycle | 43 | 97 | 102 | 84 | -40 | 28 | -12 | 30 | 44 | 70 | 48 | 59 |
| Working Capital Days | 7 | 15 | 9 | 23 | -13 | -17 | 59 | 64 | 75 | 50 | -296 | -49 |
| ROCE % | 64% | 47% | 53% | 60% | 34% | 26% | 25% | 27% | 25% | 17% | 11% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund | 6,482,100 | 2.72 | 1034.15 | N/A | N/A | N/A |
| HDFC Hybrid Equity Fund | 2,459,629 | 1.59 | 392.41 | N/A | N/A | N/A |
| Franklin India Small Cap Fund | 1,866,828 | 2.2 | 297.83 | N/A | N/A | N/A |
| DSP Small Cap Fund | 1,230,000 | 1.15 | 196.23 | N/A | N/A | N/A |
| Franklin India Flexi Cap Fund | 1,224,569 | 0.98 | 195.37 | N/A | N/A | N/A |
| UTI Flexi Cap Fund | 1,217,751 | 0.76 | 194.28 | 2,573,067 | 2025-12-07 01:12:50 | -52.67% |
| Franklin India Opportunities Fund | 771,388 | 1.48 | 123.07 | N/A | N/A | N/A |
| HDFC Large and Mid Cap Fund | 675,000 | 0.37 | 107.69 | N/A | N/A | N/A |
| HDFC Multi Cap Fund | 675,000 | 0.54 | 107.69 | N/A | N/A | N/A |
| UTI Mid Cap Fund | 643,678 | 0.85 | 102.69 | 627,981 | 2025-12-15 01:01:34 | 2.5% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 25.85 | 28.82 | 28.10 | 29.89 | 26.16 |
| Diluted EPS (Rs.) | 25.81 | 28.79 | 28.07 | 29.88 | 26.14 |
| Cash EPS (Rs.) | 50.67 | 42.61 | 36.12 | 34.61 | 29.32 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 209.57 | 190.11 | 163.30 | 140.35 | 116.10 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 209.57 | 190.11 | 163.30 | 140.35 | 116.10 |
| Revenue From Operations / Share (Rs.) | 212.46 | 147.70 | 123.92 | 99.10 | 89.25 |
| PBDIT / Share (Rs.) | 76.03 | 51.36 | 40.29 | 37.60 | 32.35 |
| PBIT / Share (Rs.) | 52.87 | 37.94 | 31.68 | 32.84 | 29.19 |
| PBT / Share (Rs.) | 35.89 | 31.70 | 29.76 | 32.53 | 29.05 |
| Net Profit / Share (Rs.) | 27.50 | 29.19 | 27.51 | 29.85 | 26.16 |
| NP After MI And SOA / Share (Rs.) | 25.83 | 28.82 | 28.10 | 29.88 | 26.16 |
| PBDIT Margin (%) | 35.78 | 34.77 | 32.51 | 37.93 | 36.24 |
| PBIT Margin (%) | 24.88 | 25.68 | 25.56 | 33.13 | 32.70 |
| PBT Margin (%) | 16.89 | 21.46 | 24.01 | 32.82 | 32.55 |
| Net Profit Margin (%) | 12.94 | 19.76 | 22.20 | 30.12 | 29.30 |
| NP After MI And SOA Margin (%) | 12.15 | 19.50 | 22.67 | 30.14 | 29.30 |
| Return on Networth / Equity (%) | 12.32 | 15.15 | 17.40 | 21.28 | 22.52 |
| Return on Capital Employeed (%) | 12.74 | 11.42 | 13.36 | 21.53 | 23.76 |
| Return On Assets (%) | 5.00 | 5.56 | 10.42 | 17.87 | 19.35 |
| Long Term Debt / Equity (X) | 0.60 | 0.25 | 0.29 | 0.02 | 0.00 |
| Total Debt / Equity (X) | 0.84 | 1.06 | 0.37 | 0.02 | 0.00 |
| Asset Turnover Ratio (%) | 0.41 | 0.37 | 0.52 | 0.61 | 0.67 |
| Current Ratio (X) | 0.88 | 0.90 | 1.73 | 3.14 | 2.80 |
| Quick Ratio (X) | 0.64 | 0.83 | 1.43 | 2.55 | 2.23 |
| Inventory Turnover Ratio (X) | 11.05 | 1.11 | 1.26 | 1.31 | 1.48 |
| Dividend Payout Ratio (NP) (%) | 28.43 | 0.00 | 26.15 | 20.10 | 21.02 |
| Dividend Payout Ratio (CP) (%) | 14.99 | 0.00 | 20.01 | 17.34 | 18.75 |
| Earning Retention Ratio (%) | 71.57 | 0.00 | 73.85 | 79.90 | 78.98 |
| Cash Earning Retention Ratio (%) | 85.01 | 0.00 | 79.99 | 82.66 | 81.25 |
| Interest Coverage Ratio (X) | 4.48 | 8.24 | 20.94 | 123.26 | 243.78 |
| Interest Coverage Ratio (Post Tax) (X) | 2.62 | 5.68 | 15.30 | 98.87 | 198.08 |
| Enterprise Value (Cr.) | 21908.96 | 13413.39 | 8575.56 | 9359.51 | 8168.96 |
| EV / Net Operating Revenue (X) | 7.57 | 6.68 | 5.09 | 6.95 | 6.74 |
| EV / EBITDA (X) | 21.16 | 19.20 | 15.65 | 18.31 | 18.60 |
| MarketCap / Net Operating Revenue (X) | 6.67 | 5.70 | 4.62 | 6.95 | 6.77 |
| Retention Ratios (%) | 71.56 | 0.00 | 73.84 | 79.89 | 78.97 |
| Price / BV (X) | 6.76 | 4.42 | 3.54 | 4.91 | 5.21 |
| Price / Net Operating Revenue (X) | 6.67 | 5.70 | 4.62 | 6.95 | 6.77 |
| EarningsYield | 0.01 | 0.03 | 0.04 | 0.04 | 0.04 |
After reviewing the key financial ratios for ERIS Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 25.85. This value is within the healthy range. It has decreased from 28.82 (Mar 24) to 25.85, marking a decrease of 2.97.
- For Diluted EPS (Rs.), as of Mar 25, the value is 25.81. This value is within the healthy range. It has decreased from 28.79 (Mar 24) to 25.81, marking a decrease of 2.98.
- For Cash EPS (Rs.), as of Mar 25, the value is 50.67. This value is within the healthy range. It has increased from 42.61 (Mar 24) to 50.67, marking an increase of 8.06.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 209.57. It has increased from 190.11 (Mar 24) to 209.57, marking an increase of 19.46.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 209.57. It has increased from 190.11 (Mar 24) to 209.57, marking an increase of 19.46.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 212.46. It has increased from 147.70 (Mar 24) to 212.46, marking an increase of 64.76.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 76.03. This value is within the healthy range. It has increased from 51.36 (Mar 24) to 76.03, marking an increase of 24.67.
- For PBIT / Share (Rs.), as of Mar 25, the value is 52.87. This value is within the healthy range. It has increased from 37.94 (Mar 24) to 52.87, marking an increase of 14.93.
- For PBT / Share (Rs.), as of Mar 25, the value is 35.89. This value is within the healthy range. It has increased from 31.70 (Mar 24) to 35.89, marking an increase of 4.19.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 27.50. This value is within the healthy range. It has decreased from 29.19 (Mar 24) to 27.50, marking a decrease of 1.69.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 25.83. This value is within the healthy range. It has decreased from 28.82 (Mar 24) to 25.83, marking a decrease of 2.99.
- For PBDIT Margin (%), as of Mar 25, the value is 35.78. This value is within the healthy range. It has increased from 34.77 (Mar 24) to 35.78, marking an increase of 1.01.
- For PBIT Margin (%), as of Mar 25, the value is 24.88. This value exceeds the healthy maximum of 20. It has decreased from 25.68 (Mar 24) to 24.88, marking a decrease of 0.80.
- For PBT Margin (%), as of Mar 25, the value is 16.89. This value is within the healthy range. It has decreased from 21.46 (Mar 24) to 16.89, marking a decrease of 4.57.
- For Net Profit Margin (%), as of Mar 25, the value is 12.94. This value exceeds the healthy maximum of 10. It has decreased from 19.76 (Mar 24) to 12.94, marking a decrease of 6.82.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.15. This value is within the healthy range. It has decreased from 19.50 (Mar 24) to 12.15, marking a decrease of 7.35.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.32. This value is below the healthy minimum of 15. It has decreased from 15.15 (Mar 24) to 12.32, marking a decrease of 2.83.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.74. This value is within the healthy range. It has increased from 11.42 (Mar 24) to 12.74, marking an increase of 1.32.
- For Return On Assets (%), as of Mar 25, the value is 5.00. This value is within the healthy range. It has decreased from 5.56 (Mar 24) to 5.00, marking a decrease of 0.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. It has increased from 0.25 (Mar 24) to 0.60, marking an increase of 0.35.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.84. This value is within the healthy range. It has decreased from 1.06 (Mar 24) to 0.84, marking a decrease of 0.22.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.41. It has increased from 0.37 (Mar 24) to 0.41, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1.5. It has decreased from 0.90 (Mar 24) to 0.88, marking a decrease of 0.02.
- For Quick Ratio (X), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 1. It has decreased from 0.83 (Mar 24) to 0.64, marking a decrease of 0.19.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 11.05. This value exceeds the healthy maximum of 8. It has increased from 1.11 (Mar 24) to 11.05, marking an increase of 9.94.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 28.43. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 28.43, marking an increase of 28.43.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 14.99. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 24) to 14.99, marking an increase of 14.99.
- For Earning Retention Ratio (%), as of Mar 25, the value is 71.57. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 71.57, marking an increase of 71.57.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 85.01. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 85.01, marking an increase of 85.01.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.48. This value is within the healthy range. It has decreased from 8.24 (Mar 24) to 4.48, marking a decrease of 3.76.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.62. This value is below the healthy minimum of 3. It has decreased from 5.68 (Mar 24) to 2.62, marking a decrease of 3.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 21,908.96. It has increased from 13,413.39 (Mar 24) to 21,908.96, marking an increase of 8,495.57.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.57. This value exceeds the healthy maximum of 3. It has increased from 6.68 (Mar 24) to 7.57, marking an increase of 0.89.
- For EV / EBITDA (X), as of Mar 25, the value is 21.16. This value exceeds the healthy maximum of 15. It has increased from 19.20 (Mar 24) to 21.16, marking an increase of 1.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.67. This value exceeds the healthy maximum of 3. It has increased from 5.70 (Mar 24) to 6.67, marking an increase of 0.97.
- For Retention Ratios (%), as of Mar 25, the value is 71.56. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 71.56, marking an increase of 71.56.
- For Price / BV (X), as of Mar 25, the value is 6.76. This value exceeds the healthy maximum of 3. It has increased from 4.42 (Mar 24) to 6.76, marking an increase of 2.34.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.67. This value exceeds the healthy maximum of 3. It has increased from 5.70 (Mar 24) to 6.67, marking an increase of 0.97.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in ERIS Lifesciences Ltd:
- Net Profit Margin: 12.94%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.74% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.32% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.62
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 46.1 (Industry average Stock P/E: 48.16)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.84
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.94%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Ahmedabad Gujarat 380054 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Amit Bakshi | Chairperson & Managing Director |
| Mr. Krishnakumar Vaidyanathan | COO & Executive Director |
| Mr. Inderjeet Singh Negi | Executive Director |
| Mr. Kaushal Shah | Executive Director |
| Mr. Rajeev Dalal | Independent Director |
| Mr. Sujesh Vasudevan | Independent Director |
| Ms. Kalpana Unadkat | Independent Director |
| Mr. Prashant Gupta | Independent Director |
FAQ
What is the intrinsic value of ERIS Lifesciences Ltd?
ERIS Lifesciences Ltd's intrinsic value (as of 23 January 2026) is ₹1090.18 which is 21.29% lower the current market price of ₹1,385.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹19,185 Cr. market cap, FY2025-2026 high/low of ₹1,910/1,097, reserves of ₹3,078 Cr, and liabilities of ₹7,160 Cr.
What is the Market Cap of ERIS Lifesciences Ltd?
The Market Cap of ERIS Lifesciences Ltd is 19,185 Cr..
What is the current Stock Price of ERIS Lifesciences Ltd as on 23 January 2026?
The current stock price of ERIS Lifesciences Ltd as on 23 January 2026 is ₹1,385.
What is the High / Low of ERIS Lifesciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of ERIS Lifesciences Ltd stocks is ₹1,910/1,097.
What is the Stock P/E of ERIS Lifesciences Ltd?
The Stock P/E of ERIS Lifesciences Ltd is 46.1.
What is the Book Value of ERIS Lifesciences Ltd?
The Book Value of ERIS Lifesciences Ltd is 227.
What is the Dividend Yield of ERIS Lifesciences Ltd?
The Dividend Yield of ERIS Lifesciences Ltd is 0.52 %.
What is the ROCE of ERIS Lifesciences Ltd?
The ROCE of ERIS Lifesciences Ltd is 12.2 %.
What is the ROE of ERIS Lifesciences Ltd?
The ROE of ERIS Lifesciences Ltd is 12.9 %.
What is the Face Value of ERIS Lifesciences Ltd?
The Face Value of ERIS Lifesciences Ltd is 1.00.